IDEAYA Launches Phase 1/2 Study of IDE892 in MTAP-Deleted Cancers
SOUTH SAN FRANCISCO, Calif., June 15, 2026 IDEAYA Biosciences has announced the initiation of a Phase 1/2 clinical combination...
AI drug discovery Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SOUTH SAN FRANCISCO, Calif., June 15, 2026 IDEAYA Biosciences has announced the initiation of a Phase 1/2 clinical combination...
TAMPA, Fla., June 15, 2026 TuHURA Biosciences, Inc. has announced the filing of an Investigational New Drug (IND) application...
